GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Santhera Pharmaceuticals Holding AG (XSWX:SANN) » Definitions » Asset Impairment Charge

Santhera Pharmaceuticals Holding AG (XSWX:SANN) Asset Impairment Charge : CHF0.00 Mil (TTM As of Jun. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Santhera Pharmaceuticals Holding AG Asset Impairment Charge?

Santhera Pharmaceuticals Holding AG's Asset Impairment Charge for the six months ended in Jun. 2023 was CHF0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Jun. 2023 was CHF0.00 Mil.

Santhera Pharmaceuticals Holding AG Asset Impairment Charge Historical Data

The historical data trend for Santhera Pharmaceuticals Holding AG's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Santhera Pharmaceuticals Holding AG Asset Impairment Charge Chart

Santhera Pharmaceuticals Holding AG Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Asset Impairment Charge
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Santhera Pharmaceuticals Holding AG Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Asset Impairment Charge Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Santhera Pharmaceuticals Holding AG Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF0.00 Mil.

Santhera Pharmaceuticals Holding AG Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Santhera Pharmaceuticals Holding AG's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Santhera Pharmaceuticals Holding AG (XSWX:SANN) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Santhera Pharmaceuticals Holding AG (XSWX:SANN) » Definitions » Asset Impairment Charge
Comparable Companies
XSWX:MOLN XSWX:NWRN XSWX:RLF XSWX:ADXN XSWX:EVE XSWX:KNRS XSWX:SPEX XSWX:XLS XSWX:BSLN XSWX:IDIA OCSE:NOVO B VRTX REGN ASX:CSL XKRX:207940 MRNA XKRX:068270 XBRU:ARGX XBRU:UCB BNTX
Traded in Other Exchanges
SPHDF:USA SANNz:UK
Address
Hohenrainstrasse 24, Pratteln, CHE, 4133
Website
https://www.santhera.com
Santhera Pharmaceuticals Holding AG is a specialty pharmaceutical company focused on the development and commercialization of products for the treatment of mitochondrial and neuromuscular diseases, an area that includes many orphan and niche indications with high unmet medical needs. It has one operating segment, namely the development and commercialization of products for the treatment of neuro-ophthalmological, pulmonary, and neuromuscular diseases. The company derives most of its revenue from the European Union.

Santhera Pharmaceuticals Holding AG (XSWX:SANN) Headlines

No Headlines